Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

33.50 -0.78 (-2.28%)
Streaming Delayed Price Updated: 11:55 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents
From Moderna, Inc.
Via Business Wire
Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
From Moderna, Inc.
Via Business Wire
Moderna to Present at Upcoming Investor Conferences in November 2021
From Moderna, Inc.
Via Business Wire
Moderna Named a Top Employer by Science for Seventh Consecutive Year
From Moderna, Inc.
Via Business Wire
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Announces Swissmedic Authorizes Booster Dose of Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union
From Moderna, Inc.
Via Business Wire
Moderna Announces European Medicines Agency’s Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna’s COVID-19 Vaccine in the European Union
From Moderna, Inc.
Via Business Wire
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
From Moderna, Inc.
Via Business Wire
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via Business Wire
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via Business Wire
Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine
Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing... 
Via FinancialNewsMedia
Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021
From Moderna, Inc.
Via Business Wire
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
From Moderna, Inc.
Via Business Wire
Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
From Moderna, Inc.
Via Business Wire
Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines
From Moderna, Inc.
Via Business Wire
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
From Moderna, Inc.
Via Business Wire
Moderna to Invest in New Science Center in Cambridge, MA
From Moderna, Inc.
Via Business Wire
Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells
Via FinancialNewsMedia
Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
From Moderna, Inc.
Via Business Wire
Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Rare Adverse Effects Continue to Fuel Covid-19 Vaccine Hesitancy, Despite Safety Breakthroughs
Via FinancialNewsMedia
Scientists Rapidly Advancing Cancer Vaccine Prospects Using Same Technology as Covid-19 Shots
Via FinancialNewsMedia
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
Via FinancialNewsMedia
Moderna Announces Health Canada Approves its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
From Moderna, Inc.
Via Business Wire
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
From Moderna, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.